Work

A randomized‐controlled trial to investigate the effects of rivoglitazone, a novel PPAR gamma agonist on glucose–lipid control in type 2 diabetes

Year: 2011

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Diabetes Obesity and Metabolism

DOI: 10.1111/j.1463-1326.2011.01411.x

Authors: A. P. S. Kong, A. Yamasaki, R. Ozaki, H. Saito, T. Asami, S. Ohwada, G. T. C. Ko, C. K. Wong, G. T. C. Leung, K. F. Lee, C. Y. Yeung, J. C. N. Chan

Institutions: Chinese University of Hong Kong, Prince of Wales Hospital, Daiichi-Sankyo (Japan), Alice Ho Miu Ling Nethersole Hospital, Kwong Wah Hospital, Pamela Youde Nethersole Eastern Hospital

Language: English

Topic: Diabetes Treatment and Management

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1995232262

FWCI: 1.048

Cites: 16

Cited by: 21

Related to: 10